Zonisamide attenuates MPTP neurotoxicity in marmosets

Journal of Pharmacological Sciences

Volumn 114, Issue 3, 2010, Pages 298-303

  Choudhury, Mohammed Emamussalehin ^a   Moritoyo, Takashi ^a   Yabe, Hayato ^a   Nishikawa, Noriko ^a   Nagai, Masahiro ^a   Kubo, Madoka ^a   Matsuda, Seiji ^a   Nomoto, Masahiro ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Marmoset; MPTP; Selegiline; Tyrosine hydroxylase (TH) positive dopaminergic neuron; Zonisamide

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; SELEGILINE; TYROSINE 3 MONOOXYGENASE; ZONISAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL SIZE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MARMOSET; NEUROTOXICITY; NONHUMAN; SUBSTANTIA NIGRA;

EID: 78649438482     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10120FP     Document Type: Article

References (24)

1. Uno H, Kurosawa M, Masuda Y, Nishimura H. Studies on 3- substituted 1,2 benzisoxazole derivatives. 6. Syntheses of 3- (sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J Med Chem. 1979;22:180-183.
2. Ito T, Yamaguchi T, Miyazaki H, Sekine Y, Shimizu M, Ishida S, et al. Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. Arzneimittelforschung. 1982;32:1581-1586.
3. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987;413:185-188.
4. Rock DM, MacDonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989;3:138-143.
5. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 1992;12:21-27.
6. Hayakawa T, Higuchi Y, Nigami H, Hattori H. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur J Pharmacol. 1994;257:131-136.
7. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001;41: 397-399.
8. Miwa H. Zonisamide for the treatment of Parkinson's disease. Expert Rev Neurother. 2007;7:1077-1083.
9. Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68: 45-50.
10. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N, Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res. 2008;60:106-113.
11. Sonsalla PK, Wong LY, Winnik B, Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010;221:329-334.
12. Yano R, Yokoyama H, Kuroiwa H, Kato H, Araki T. A novel anti- Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. J Mol Neurosci. 2009;39:211-219.
13. Yabe H, Choudhury ME, Kubo M, Nishikawa N, Nagai M, Nomoto M. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci. 2009;110:64-68.
14. Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett. 1989;101:305-310.
15. Nomoto M, Iwata SI, Kaseda S, Fukuda T, Nakagawa S. Increased dopamine turnover in the putamen after MPTP treatment in common marmosets. Brain Res. 1997;767:235-238.
16. Stephan H, Baron G, Schwerdtfeger WK. The brain of the common marmoset (Callithrix jacchus). Berlin, Heidelberg: Springer- Verlag; 1980.
17. Nomoto M, Jenner P, Marsden CD. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett. 1985;57: 37-41.
18. Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in common marmoset. Synapse. 1997;26:301-316.
19. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10: 687-693.
20. Matsumoto K, Miyazaki H, Fujii T, Kagemoto A, Maeda T, Hashimoto M. Absorption, distribution and excretion of 3- (sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Arzneimittelforschung. 1983;33:961-968.
21. Lange KW, Löschmann PA, Sofic E, Burg M, Horowski R, Kalveram KT, et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch Pharmacol. 1993; 348:586-592.
22. Kass GE, Wright JM, Nicotera P, Orrenius S. The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch Biochem Biophys. 1988;260:789-797.
23. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol. 1984;106:209-210.
24. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984;311:467-469.